Core Viewpoint - The article discusses the emerging significance of Extracellular Matrix (ECM) in anti-aging skincare, highlighting the potential of N-acetylneuraminic acid (also known as "Nectar Acid") as a key ingredient in this new approach to skincare [2][3][15]. Group 1: ECM and Anti-Aging - ECM has been identified as the thirteenth hallmark of aging, representing a new pathway for anti-aging technology in the beauty industry [2][8]. - Major beauty companies like L'Oréal, Estée Lauder, Shiseido, and others are actively investing in ECM-related research and development, indicating a competitive landscape [8][11]. Group 2: N-acetylneuraminic Acid (Nectar Acid) - N-acetylneuraminic acid has recently been approved by the National Medical Products Administration in China, marking its transition from experimental to a recognized cosmetic ingredient [3][15]. - This ingredient exhibits multiple biological activities, including anti-wrinkle, brightening, anti-inflammatory properties, and the ability to regulate ECM homeostasis [15][22]. Group 3: Mechanisms and Efficacy - N-acetylneuraminic acid significantly enhances collagen gene promoter activity, leading to a 252% increase in type I collagen synthesis at a concentration of 0.2% [18]. - It acts as a stabilizer for ECM by neutralizing reactive oxygen species (ROS) and inhibiting matrix metalloproteinases (MMP-1, MMP-3, MMP-9), thereby reducing collagen degradation [20][22]. Group 4: Market Potential and Applications - The successful incorporation of N-acetylneuraminic acid into the cosmetic ingredient directory opens up new market opportunities and enhances its commercial value [26][27]. - The ingredient's dual application in both topical and oral beauty products aligns with traditional Asian wellness practices, providing a strong foundation for cross-category integration [26][28]. Group 5: Research and Development - The company has invested over 30 million yuan in the industrialization of N-acetylneuraminic acid, overcoming traditional extraction challenges to achieve high purity and yield [28][29]. - Ongoing research focuses on multi-omics studies to validate the ingredient's efficacy across various biological pathways, enhancing its appeal in the anti-aging market [25][34].

Core Viewpoint - The beauty industry is increasingly entering the medical aesthetics channel, with over 20 beauty brands adopting a dual beauty strategy of "medical aesthetics + beauty" to enhance their market presence and professional credibility [2][6][30]. Group 1: Market Overview - The medical aesthetics market in China is experiencing strong growth, with 18,584 compliant specialized medical aesthetics institutions reported as of January 2024 [6][7]. - The main active regions for medical aesthetics consumption are concentrated in the Pearl River Delta, Yangtze River Delta, and Chengdu-Chongqing areas [7][8]. Group 2: Industry Structure - Medical aesthetics institutions can be categorized into three types: public hospitals, large chain private hospitals, and small private hospitals and clinics [4][5]. - The development of the domestic medical aesthetics industry has gone through three main stages: initiation (1994-2000), gradual standardization (2000-2010), and rapid development (2010-present) [5]. Group 3: Brand Strategies - Many beauty companies have established significant medical aesthetics channel layouts, such as Huaxi Biological covering 7,000 medical institutions and Juzhi Biological entering approximately 1,700 public hospitals and 3,000 private hospitals and clinics [8][10]. - International beauty brands are also accelerating their medical aesthetics channel expansion, with brands like SkinCeuticals and Estée Lauder entering high-end medical aesthetics lines [10][12]. Group 4: Consumer Trends - There is a growing consumer demand for effective skincare solutions that combine beauty products with medical treatments, reflecting a trend towards the integration of lifestyle beauty and medical aesthetics [17][20]. - Consumers are increasingly seeking products with professional medical backing and comprehensive management solutions from pre-operative care to post-operative recovery [18][20]. Group 5: Challenges and Opportunities - Despite the initial success of some brands in the medical aesthetics channel, challenges remain, including product quality inconsistency and the need for effective consumer education [16][18][20]. - The dual beauty model is becoming a significant trend, with medical aesthetics companies also venturing into lifestyle beauty, leveraging their technical expertise and clinical data [22][23]. Group 6: Future Outlook - The competition in the medical aesthetics channel is expected to intensify, with beauty brands needing to establish unique advantages through solid technical research and deep medical collaboration [29][30]. - The future winners in this space will be those who can embed "professional trust" in the medical aesthetics channel and leverage "real clinical value" to gain endorsements from both doctors and consumers [30].

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][32]. Core Insights - The beauty care sector saw significant activity, with Douyin's beauty category GMV exceeding 20 billion yuan in June, where skincare accounted for 66.4% and color cosmetics for 33.6% [3][24]. - Notable companies like MINISO achieved over 100 million yuan in sales within nine months of opening their global flagship store [4][29]. - The report highlights the performance of key companies, with projected net profits for Xiaoshangpin City expected to be between 1.63 billion to 1.7 billion yuan, marking a year-on-year increase of 12.57% to 17.40% [30]. Market Performance - During the week of June 30 to July 4, 2025, the retail trade, social services, and beauty care sectors experienced declines of 0.16%, 0.74%, and 0.55% respectively, ranking 27th, 17th, and 29th among 31 primary industries [14][18]. - The report notes that the education, professional chain, and trade sectors saw the highest gains, with increases of 7.47%, 7.42%, and 5.2% respectively [2][14]. Key Industry Events and News - The report discusses various industry events, including the approval of a topical finasteride spray by NMPA, marking it as the first and only approved product for male androgenetic alopecia [3][24]. - L'Oréal announced the acquisition of the professional hair care brand Color Wow, valued at approximately 10 billion yuan [3][26]. - The report also mentions the performance of companies like Huaxi Biological, which reported significant revenue declines for its brands in 2024 [31]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Juzhi Biological, Marubi Biological, and others within the beauty care sector [5][32].

Core Viewpoint - The article highlights the upcoming Synbio China 2025 event, focusing on the integration of scientists, entrepreneurs, and investors in the field of synthetic biology, emphasizing its strategic importance for the development of China's bio-economy [33]. Event Details - The Synbio China 2025 event will take place on August 1-2, 2025, at the Suzhou International Expo Center, alongside the 7th CMC-China Expo [1]. - Confirmed attendees include experts from various universities such as Beijing University of Chemical Technology, Shanghai Jiao Tong University, and East China University of Science and Technology, as well as representatives from companies like Micro Factory and Henan Biological Industry Group [2]. Agenda Highlights - The agenda includes lectures from academicians and experts, covering topics such as the opportunities and challenges in the industrialization of synthetic biology, and innovative pathways for non-grain biomass potential [6][7]. - Specific sessions will focus on enabling technologies, including enzyme engineering and CRISPR/Cas9 applications, as well as the development of bio-based materials and their industrial applications [8][10]. Industry Challenges - The article discusses the rapid dissemination of synthetic biology concepts in China, while also addressing challenges such as achieving scalable production, realizing the value of synthetic biological products, and fostering innovation in core competitiveness [33]. Networking Opportunities - The event aims to facilitate face-to-face interactions among founders, industry experts, investors, and government representatives, providing a platform for project promotion and industry guidance [35]. Participation and Registration - Attendees are encouraged to register for free through a QR code provided in the article, ensuring access to the event and its networking opportunities [4][12]. Additional Information - The 7th CMC-China Expo is expected to attract around 20,000 participants, featuring 450 exhibiting companies and 600 invited guests, with multiple forums dedicated to cutting-edge topics in the industry [79].

1. Report Industry Investment Rating - No industry investment rating information is provided in the report. 2. Core Viewpoints of the Report - The report regularly updates the latest information on private exchangeable bond (private EB) projects from public channels and conducts basic element tracking on private exchangeable bond projects, emphasizing that the issuance terms and progress may change, and the final prospectus and relevant underwriters should be referred to [1]. 3. Summary by Relevant Catalogs 3.1 New Project Information - There is no new project information this week, and some projects are not listed due to compliance reasons [2]. 3.2 Project Status Table - The table lists the details of multiple private EB projects, including bond names, lead underwriters, scales, underlying stocks, project statuses, and update dates. Projects include those from companies such as Shudao Investment Group Co., Ltd., China Pingmei Shenma Group Co., Ltd., and Guangdong Shunde Holdings Group Co., Ltd., with statuses of "Passed", "Feedback Received", and "Accepted" [3].

Group 1 - The Shandong provincial government has implemented a plan to boost consumption, focusing on six key tasks and 20 specific measures, including the enhancement of health consumption and the development of health-related industries such as health tourism and biomedicine [2] - The hyaluronic acid industry in Shandong, led by companies like Huaxi Bio and Furuida, has formed a trillion-level industrial cluster, responding to rapidly changing consumer aesthetics and demands [2][14] - Huaxi Bio has emphasized the importance of establishing scientific and unified testing standards for the industry, following a public dispute with competitor Juzhi Bio regarding product quality and testing methods [3][6] Group 2 - The competition between Huaxi Bio and Juzhi Bio has highlighted the challenges in the hyaluronic acid market, with Huaxi Bio accusing Juzhi Bio of misleading research that undermines the hyaluronic acid industry [6][8] - Despite the ongoing competition, the hyaluronic acid market is experiencing a decline in product prices, with some high-end products dropping to as low as 10% of their previous prices [9][10] - The three major players in the hyaluronic acid sector, including Huaxi Bio, have reported negative growth in revenue and net profit in recent quarters, contrasting with the strong performance of companies in the recombinant collagen sector [10][11] Group 3 - Huaxi Bio has maintained a leading position in the global hyaluronic acid market, holding a 44% share of global sales in 2021 and actively participating in the development of industry standards [16] - The company is undergoing a strategic upgrade, investing over 100 million yuan in innovative business areas such as regenerative medicine and nutritional science [16] - Furuida is also expanding into the recombinant collagen market, recognizing the need for transformation and innovation in response to industry pressures [19][20] Group 4 - Experts suggest that the hyaluronic acid industry has reached maturity and needs to explore a "second growth curve" to maintain competitiveness and sustainable development [21] - The relationship between hyaluronic acid and collagen is viewed as complementary rather than competitive, with both having unique advantages in various applications [20] - The industry is focusing on developing new business models and products that align with consumer health trends, including functional foods and personalized raw materials [19][20]

Summary of the Conference Call for Furuida Company Overview - **Company**: Furuida - **Brands**: Aier Doctor, Yilian, Kemei Key Points and Arguments Brand Adjustments and Performance - Aier Doctor brand is undergoing adjustments expected to complete by the end of 2025, with current performance anticipated to remain flat due to market price issues and product discontinuation [2][3] - The new 287 mask, an upgraded version of the probiotic mask, is expected to drive growth in the second half of the year [2][16] - Yilian brand has completed its upgrade, focusing on high-moisture ingredients, and is projected to achieve double-digit growth by 2025 [2][4] - Kemei brand has made breakthroughs in transdermal technology, allowing collagen to be absorbed through the skin, with expectations of triple-digit growth by 2025 [2][5] Financial Projections - Overall revenue for Furuida in 2025 is expected to be flat or slightly increase, with Yilian projected to grow by 15% to 20% and Kemei by triple digits [2][6][8] - Aier Doctor's performance is expected to stabilize after adjustments, with optimism for 2026 if the brand's strategy is successful [6][8] Product Innovations - Introduction of new ingredient royal jelly acid, which has anti-aging and repair functions, planned for launch under Aier Doctor in July [2][12][13] - The new product series will include various skincare items priced competitively compared to luxury brands [14][36] Market Strategy - Furuida's online sales channels are currently at a ratio of 9:1 compared to offline, with plans to adjust to 80% online and 20% offline [19] - The company is focusing on high-margin products and reducing reliance on external raw materials to improve profitability, especially on platforms like Douyin [20] Challenges and Opportunities - The company faces challenges with Aier Doctor's brand performance but is actively addressing issues such as channel pricing and product strategy [3][7] - Furuida is exploring acquisition opportunities to expand into new markets and enhance its product offerings [25][26] Consumer Engagement - The company is leveraging live streaming and offline events to promote new products, aiming to enhance brand awareness and consumer engagement [27][28] Future Outlook - Furuida is optimistic about the market response to new products, particularly the royal jelly acid series, which is currently in testing [17] - The company is committed to maintaining stable growth in its pharmaceutical and raw material sectors while exploring new product lines [22][21] Additional Important Information - The company is not currently considering selling exclusive raw materials but is open to other forms of collaboration [15] - Kemei's current sales strategy includes a focus on online channels, with a strong average transaction value of 699 yuan in live streaming [9][10] - The company is also testing new health products in the oral collagen segment, responding to growing consumer interest in wellness [21]

Core Viewpoint - The Chinese cosmetics market has reached unprecedented heights, prompting a fundamental question: how to transform from "big" to "strong" and build core competitiveness that transcends cycles [2][6]. Group 1: Industry Overview - The Chinese cosmetics industry has evolved from a "channel king" model to a "traffic supremacy" model over the past decade, but is now facing the end of traffic dividends and increasing competition [6]. - According to the China Cosmetics Association, 22 Chinese brands made it to the Top 50 list, with a total retail value of 93.54 billion yuan, accounting for 39.98% of the total retail scale of the Top 50 brands [6]. - The overall market share of Chinese brands reached 55.2%, indicating that their success is not solely driven by leading enterprises but also by home-field and quantity advantages [6]. Group 2: Key Challenges and Opportunities - The industry is undergoing profound transformation and challenges, necessitating a return to the core values of brand building to ensure long-term stability and growth [6]. - The arrival of the "brand era" in the Chinese cosmetics industry hinges on four dimensions: R&D innovation, cultural heritage, sustainable development, and brand building [6]. Group 3: Conference Highlights - The conference featured discussions on enhancing brand value, with notable speakers from L'Oréal, Procter & Gamble, and other leading companies sharing insights [7][9]. - L'Oréal's North Asia President emphasized three strategic pillars for brand value enhancement: consumer-centric brand building, innovation driven by science and technology, and collaborative future creation [9]. - The conference also addressed the issue of "involution" in the market, highlighting its characteristics and the need for a shift towards quality and innovation [18][19]. Group 4: Brand Value Enhancement Strategies - The brand value roundtable discussed whether premium capability or user scale is more critical to brand value, with varying opinions from industry leaders [12]. - Strategies for enhancing brand value include trust elevation, experiential enhancement, asset elevation, and operational elevation [10]. Group 5: Sustainable Growth Paths - A report analyzed high-growth brands and identified key growth paths for top, mid-tier, and emerging brands, emphasizing the importance of system capabilities for larger brands and niche focus for mid-tier brands [22]. - The conference proposed a new ecosystem for the industry, advocating for collaboration and shared growth to combat fierce competition [31]. Group 6: Regulatory Environment - Recent government measures aim to combat "involution" in the market, including the revision of the Anti-Unfair Competition Law to prohibit forced low-price sales and data abuse [17]. - The introduction of the "2025 Cosmetics Industry Data Statistical Standards" aims to address data fragmentation and enhance decision-making capabilities within the industry [36][39]. Group 7: Future Outlook - The industry is expected to transition from a phase of chaotic growth to a more structured and value-driven approach, focusing on R&D depth, cultural richness, and ecological health [44]. - The next few years will be crucial for the Chinese cosmetics industry to evolve into a period that nurtures great brands through solid groundwork and innovation [45].

Investment Rating - The report rates the cosmetics and medical beauty industry as "Positive" [2][3] Core Viewpoints - The cosmetics retail sales growth for January to May 2025 is 4.1%, an increase of 2 percentage points compared to the same period last year, indicating a steady recovery in demand [3] - The performance of leading brands remains strong, with double-digit growth, supported by the theme of self-care in new consumption trends, leading to a positive outlook for the first half of 2025 [3] - The 618 shopping festival saw strong performances from domestic brands, with notable rankings on platforms like Tmall and Douyin [3] Summary by Sections Cosmetics Industry Outlook - The report anticipates significant revenue and net profit growth for major companies in Q2 and H1 2025, with specific forecasts: - Up Beauty Co. is expected to see a revenue increase of 16% and a net profit increase of 25% [3] - Marubi is projected to grow revenue by 22% and net profit by 28% in Q2 2025 [3] - Proya is expected to achieve a revenue growth of 10% and net profit growth of 15% in Q2 2025 [3] Key Companies Performance - Notable companies and their expected performance include: - Mao Geping is projected to have a revenue increase of 38% and net profit increase of 35% in H1 2025 [3] - Ruibin is expected to see a revenue increase of 15% and net profit increase of 15% in Q2 2025 [3] - Huaxi Biological is expected to maintain stable performance with a 0% revenue growth and a 10% net profit increase in Q2 2025 [3] Investment Recommendations - The report recommends focusing on companies with strong brand matrices and comprehensive product layouts, such as Up Beauty Co., Marubi, and Proya, which are expected to benefit from the live e-commerce traffic [3] - It also highlights the importance of niche market players like Ruibin and Mao Geping, who are positioned to capitalize on the rise of personal care and domestic beauty trends [3] - For the medical beauty sector, the report suggests focusing on companies with high R&D barriers and strong profitability, recommending companies like Aimeike and Langzi [3] E-commerce and Other Segments - The report suggests monitoring e-commerce companies like Ruibin, which is expected to see significant growth in revenue and net profit [3] - In the maternal and infant sector, Kid King is projected to exceed market expectations with a revenue increase of 10% and a net profit increase of 70% in Q2 2025 [3]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].